[1] |
Liu JY, Ayada I, Zhang XF, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh,2021.02.030.
doi: 10.1016/j.cgh,2021.02.030
|
[2] |
Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377(21):2063-2072.
doi: 10.1056/NEJMra1503519
URL
|
[3] |
M I, Singh C, Ganie MA, et al. NASH:The hepatic injury of metabolic syndrome:a brief update[J]. Int J Health Sci:Qassim, 2009, 3(2):265-270.
|
[4] |
İlyas TUNCER, Hanefi ÖZBEK, Topal C, et al. The serum levels of IL-1b, IL-6, IL-8 and TNF-a in nonalcoholic fatty liver[J]. Turkish Journal of Medical Sciences, 2003, 33(24):381-386.
|
[5] |
Day CP, James OF. Steatohepatitis:a tale of two “hits” ?[J]. Gastroenterology, 1998, 114(4):842-845.
pmid: 9547102
|
[6] |
Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J]. Metabolism, 2016, 65(8):1038-1048.
doi: 10.1016/j.metabol.2015.12.012
URL
|
[7] |
Fang YL, Chen H, Wang CL, et al. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence:From “two hit theory” to “multiple hit model”[J]. World J Gastroenterol, 2018, 24(27):2974-2983.
doi: 10.3748/wjg.v24.i27.2974
URL
|
[8] |
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease:The multiple parallel hits hypojournal[J]. Hepatology, 2010, 52(5):1836-1846.
doi: 10.1002/hep.v52:5
URL
|
[9] |
Rinaldi L, Pafundi PC, Galiero R, et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review[J]. Antioxidants, 2021, 10(2):270.
doi: 10.3390/antiox10020270
URL
|
[10] |
Li ZP, Yang SQ, Lin HZ, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease[J]. Hepatology, 2003, 37(2):343-350.
doi: 10.1053/jhep.2003.50048
URL
|
[11] |
Sun ZH, Chen X, Wang JC, et al. Complete genome sequence of probiotic Bifidobacterium animalis subsp. lactis strain V9[J]. J Bacteriol, 2010, 192(15):4080-4081.
doi: 10.1128/JB.00369-10
URL
|
[12] |
陈霞. 具有益生功能的Bifidobacterium animalis subsp. lactis V9的安全性评估、生理功效及其全基因组学研究[D]. 呼和浩特:内蒙古农业大学, 2010.
|
|
Chen X. Safety evaluation, physiological function & whole genome sequence of potential probiotic Bifidobacterium animalis subsp. lactis V9[D]. Hohhot:Inner Mongolia Agricultural University, 2010.
|
[13] |
Wong WK, Chan WK. Nonalcoholic fatty liver disease:a global perspective[J]. Clin Ther, 2021, 43(3):473-499.
doi: 10.1016/j.clinthera.2021.01.007
URL
|
[14] |
Dongiovanni P, Paolini E, Corsini A, et al. NAFLD or MAFLD diagnoses and cardiovascular diseases:from epidemiology to drug approaches[J]. European Journal of Clinical Investigation, 2021, 14(5):e13519.
|
[15] |
Cai GS, Su H, Zhang J. Protective effect of probiotics in patients with non-alcoholic fatty liver disease[J]. Medicine, 2020, 99(32):e21464.
doi: 10.1097/MD.0000000000021464
URL
|
[16] |
Kwong EK, Puri P. Gut microbiome changes in nonalcoholic fatty liver disease & alcoholic liver disease[J]. Transl Gastroenterol Hepatol, 2021, 6:3.
doi: 10.21037/tgh.2020.02.18
pmid: 33409398
|
[17] |
Bajaj JS, Heuman DM, Hylemon PB, et al. Randomised clinical trial:Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2014, 39(10):1113-1125.
doi: 10.1111/apt.2014.39.issue-10
URL
|
[18] |
Yan Y, Liu C, Zhao S, et al. Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease[J]. AMB Express, 2020, 10(1):101.
doi: 10.1186/s13568-020-01038-y
pmid: 32472368
|
[19] |
Kumar R, Goh BG, Kam JW, et al. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma[J]. Clin Mol Hepatol, 2020, 26(2):196-208.
doi: 10.3350/cmh.2019.0012
URL
|
[20] |
Zhou HP, Urso CJ, Jadeja V. Saturated fatty acids in obesity-associated inflammation[J]. J Inflamm Res, 2020, 13:1-14.
doi: 10.2147/JIR
URL
|
[21] |
蒋李妍, 肖新华. 肠道菌群与非酒精性脂肪肝病相关性研究进展[J]. 临床与病理杂志, 2016, 36(12):2060-2065.
|
|
Jiang LY, Xiao XH. Research progress on correlation between gut microbiota and non-alcoholic fatty liver disease[J]. J Clin Pathol Res, 2016, 36(12):2060-2065.
|
[22] |
Dai X, Wang BM. Role of gut barrier function in the pathogenesis of nonalcoholic fatty liver disease[J]. Gastroenterol Res Pract, 2015, 2015:1-6.
|